Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc transporter SLC39A7 (ZIP7) is a transmembrane protein encoded by the SLC39A7 gene in humans. It is primarily localized to the endoplasmic reticulum and Golgi apparatus, where it controls the release of zinc ions from these organelles into the cytosol. This regulation of cytosolic zinc levels is critical for cellular processes such as kinase activation, signal transduction, cell proliferation, glucose metabolism, and maintenance of immune cell function. ZIP7 is implicated in several cancers as a driver of proliferation and resistance to therapy and is required for normal B cell and macrophage activities. Loss or dysregulation of SLC39A7 can cause immunodeficiency, increase ER stress, and disturb cellular homeostasis. ZIP7 overexpression correlates with poor prognosis in several cancers, making it a putative therapeutic target and biomarker[1][2][3][4][6][7].
Not applicable; however, theoretically, SLC39A7 modulators would act by altering zinc efflux from intracellular stores, thereby affecting downstream signaling, especially kinases and cell proliferation pathways[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc transporter SLC39A7 (SLC39A7 (or ZIP7)).